Parent :
BIO-LIGHT LIFE SCIENCES INVESTMENTS LTD.
Type :
Core Business :
Drug development biopharmaceutical company dedicated to development of anti-obesity therapies.
Main Markets :
Overview :
OBECURE LTD., a drug development Biopharmaceutical Company dedicated to development of anti-obesity therapies, was founded in 2005 by Bio-Light, Israeli Life Sciences Investments Ltd.
OBECURE has a world wide and exclusive license from Mor Research Applications Ltd., the Technology Transfer Office of Clalit HMO to clinically develop and commercially exploit a compound for weight management proposes, as developed by Dr. Nir Barak, a specialist in nutrition and internal medicine in the Rabin Medical Center, Israel. Company compound is a generic compound. It is used extensively in Europe and other jurisdictions for the treatment of Vertigo, however, presently, it is not available on the US market following recall by the FDA, stating that while the compound is safe for use it is not efficient in treating Vertigo. OBecure intends to launch Company Compound as a weight management agent in the US.